Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Fresenius Medical Care AG & Co. KGaA FMS
$23.61
-$0.25 (-1.05%)
На 18:00, 12 мая 2023
-18.04%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
14025165491.00000000
-
week52high
30.63
-
week52low
12.79
-
Revenue
19398000000
-
P/E TTM
15
-
Beta
0.88511400
-
EPS
1.27000000
-
Last Dividend
0.71000000
-
Next Earnings Date
03 мая 2023 г. в 04:00
Описание компании
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Truist Securities | Hold | Hold | 22 июн 2022 г. |
| HSBC | Hold | 23 ноя 2021 г. | |
| RBC Capital | Sector Perform | Sector Perform | 17 ноя 2021 г. |
| Jefferies | Hold | Underperform | 11 ноя 2021 г. |
| SunTrust Robinson Humphrey | Buy | Buy | 21 мая 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates
Zacks Investment Research
10 мая 2023 г. в 12:55
Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.
Francisco Garcia Parames' Cobas Funds 4th-Quater Letter
GuruFocus
22 февр 2023 г. в 18:01
Dear Investor:
Fresenius Medical Care AG & Co. KGaA (FMS) Q4 2022 Earnings Call Transcript
Seeking Alpha
22 февр 2023 г. в 12:37
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS ) Q4 2022 Earnings Conference Call February 22, 2023 9:30 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chair & Chief Executive Officer Conference Call Participants Graham Doyle - UBS Hassan Al-Wakeel - Barclays Oliver Metzger - ODDO BHF Christoph Gretler - CS Ed Ridley-Day - Redburn Lisa Clive - Bernstein James Vane-Tempest - Jefferies Victoria Lambert - Berenberg Falko Friedrichs - Deutsche Bank Robert Davies - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. I am Nicolas, your Chorus Call operator.
Competition Coming For AbbVie's Blockbuster Humira
Seeking Alpha
16 февр 2023 г. в 01:08
It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.
Fresenius: The Company Is Climbing, And I'm At 'Buy'
Seeking Alpha
06 янв 2023 г. в 07:53
I've been unfailingly bullish in the long-term on Fresenius - both the medical care, but also the main company headquartered in Germany. Fresenius has had an extremely tricky set of years, due to company challenges and what could be characterized as mismanagement (without being wrong).